ArticleFrontiers in oncology2025
Primary malignant Brenner tumor of the ovary: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian Brenner tumor is a rare type of ovarian epithelial neoplasm, predominantly benign, with only a minority exhibiting borderline or malignant characteristics. Malignant Brenner tumors (MBTs) resemble invasive urothelial carcinoma and often coexist with benign or borderline Brenner tumors. Clinically, they frequently present with non-specific symptoms, including abdominal pain and weight loss. We report the case of a 53-year-old female who presented with a mixed echoic mass in the left adnexa identified by gynecological ultrasound. Histopathological and immunohistochemical analyses of the resected specimens confirmed the diagnosis of ovarian MBT. The patient was subsequently referred for adjuvant treatment. This case highlights the diagnostic challenge of MBT and underscores the critical role of immunohistochemistry (positive for GATA3 and p63, negative for Pax-8) in confirming the diagnosis and distinguishing MBT from its histological mimics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.